3rd Quarter - Report

IGM BIOSCIENCES, INC. for IGM BIOSCIENCES, INC.

Period 3rd Quarter 2022 Filed Oct 20, 2022 Signed by Andrew Womack

Official filing
Firm
IGM BIOSCIENCES, INC.
Client
IGM BIOSCIENCES, INC.
Income
—
Expenses
$190,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

COVID Supplemental Appropriation FY2023 Defense Appropriations S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing H.R.8236 - Department of Defense Appropriations Act, 2023 H.R.7667 - Food and Drug Amendments of 2022 S.4348 - Food and Drug Administration Safety and Landmark Advancements Act (FDASLA) of 2022 H.R.5585 - Advanced Research Projects Agency - Health (ARPA-H) Act S.3819 - Advanced Research Project Authority for Health (ARPA-H) Act H.R.6833 - Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023

LobbyistCovered position, as disclosed
ANDREW WESLEY WOMACK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 3819 (117th), S. 2076 (117th), H.R. 7667 (117th), H.R. 3932 (117th), S. 4348 (117th), H.R. 6833 (117th), S. 3799 (117th), H.R. 8236 (117th), H.R. 5585 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.